Ordering
Available Variants5 mg
CHA.34075-5mg
Price
€145.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.34075-5mg | €145.60 |
powder, ≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C12H10F2N2O3 |
|---|---|
| CAS Number | 101975-10-4 |
| Molecular Weight | 268.22 |
| UNSPSC Code | 12352202 |
| PubChem Substance ID | 24278784 |
| NACRES | NA.77 |
| MDL number | MFCD00867059 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
Zardaverine, with the chemical identifier CAS: 101975-10-4, is a phosphodiesterase inhibitor that has been investigated for its potential therapeutic applications. This compound exhibits selective inhibition of phosphodiesterase type III and type IV, which are enzymes involved in the regulation of cyclic nucleotide signaling pathways. By inhibiting these enzymes, zardaverine can increase the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), leading to various biological effects. The increased levels of these cyclic nucleotides can result in smooth muscle relaxation, anti-inflammatory effects, and modulation of immune responses. As a result, zardaverine has been explored as a potential treatment for various conditions, including cardiovascular diseases, respiratory disorders, and inflammatory diseases, although its clinical development and therapeutic use are still under investigation. Further research is needed to fully elucidate its pharmacological properties and potential clinical applications.
